IP Library Granted Patent US 7,968,104
Granted Patent B2
US 7,968,104 · App. 12/133,198 · Granted Jun 28, 2011

Use of neurotoxin therapy for treatment of urologic and related disorders

Assignee: Allergan, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,968,104
App. No.
12/133,198
Granted
Jun 28, 2011
Kind
B2
Abstract

The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.

Claims (16)

1. A method of increasing in bladder capacity in a patient with a voiding dysfunction comprising administering a therapeutically effective amount of botulinum toxin Type A to the bladder of the patient, whereby bladder capacity is increased.

2. The method of claim 1 , wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation.

3. The method of claim 1 , wherein the administration comprises an injection of botulinum toxin type A.

4. The method of claim 1 , wherein the therapeutically effective amount is 200 IU of botulinum toxin type A.

5. The method of claim 1 , wherein the administration is serial administration.

6. The method of claim 1 , wherein the therapeutically effective amount is 800 IU of botulinum toxin type A administered serially.

7. The method of claim 1 , wherein the therapeutically effective amount is about 1.4 IU/kg to 17.1 IU/kg of botulinum toxin type A.

8. The method of claim 1 , wherein the therapeutically effective amount is about 2500 IU of botulinum toxin type.

9. The method of claim 1 , wherein the administration is to the bladder wall of the bladder.

10. The method of claim 1 , wherein the administration is to the lateral bladder wall of the bladder.

11. The method of claim 1 , wherein bladder capacity increases from about 150 cc before administration to about 300-400 cc after administration.

12. A method of increasing in bladder capacity in a patient comprising administering botulinum toxin Type A to the lateral bladder wall of the patient, whereby bladder capacity is increased.

13. The method of claim 12 , wherein bladder capacity increases from about 150 cc before administration to about 300-400 cc after administration.

14. The method of claim 12 , wherein administration is up to about 2500 units.

15. The method of claim 12 , wherein administration comprises injection.

16. The method of claim 12 , wherein the administration comprises delivery by a liquid, emulsions, or suspensions.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2015
From: THE REGENTS OF THE UNIVERSITY OF COLORADO
To: ALLERGAN, INC.
Reel/Frame 036260/0570 →
Continuity (6)
Continuation 10981015 · Nov 3, 2004
Continuation 10685995 · Oct 14, 2003
Continuation 09978982 · Oct 15, 2001
Continuation 09463040
Provisional Application 60052580 · Jul 15, 1997
Related Publication 20090004312A1 · Jan 1, 2009